Organ and Tissue Transplantation and Alternatives

Organ and Tissue Transplantation and Alternatives

• SUMMARY 5SUMMARY TABLE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
  • SUMMARY FIGURE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, 2007-2013 ($ MILLIONS)

• INDUSTRY OVERVIEW
• HISTORY OF TRANSPLANTATION
• TISSUE TYPING
• IMMUNOSUPPRESSION
• Newer Immunosuppressive Drugs
• PRESERVATION
• GOVERNMENT REIMBURSEMENT
• THE TRANSPLANTATION PROCESS
• PREPARATION
• SURGERY
• RECUPERATION
• MAINTENANCE
• IMPORTANCE OF THE INDUSTRY
• ORGANS
  • TABLE 1 U.S. ORGAN TRANSPLANTS: AVERAGE FIRST YEAR COST, NUMBER OF PROCEDURES AND VALUE BY TYPE OF ORGAN TRANSPLANT, THROUGH 2013 ($ MILLIONS)
• KIDNEY
  • TABLE 2 LEADING U.S. KIDNEY TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
• LIVER
  • TABLE 3 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• HEART
  • TABLE 4 TOP FIVE U.S. HEART TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• LUNG
  • TABLE 5 TOP FIVE U.S. LUNG TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• INTESTINE
  • TABLE 6 TOP FIVE U.S. INTESTINE/SMALL BOWEL TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• PANCREAS
  • TABLE 7 TOP FIVE U.S. PANCREAS TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
• TISSUES
• DRIVERS IN THE MARKET
  • TABLE 8 TISSUE GRAFTING IN THE U.S. BY TISSUE TYPE, THROUGH 2013 (MILLION PROCEDURES)
  • FIGURE 1 U.S. MARKET FOR TISSUE GRAFTING PROCEDURES BY TYPE, 2007-2013 (MILLION PROCEDURES)
• CORNEA
• BLOOD STEM CELLS
• BONE ALLOGRAFTS
• HEART VALVES
• VASCULAR TISSUE
• SKIN AND COLLAGEN
• Applications
• WAITING LISTS OUTPACE DONATIONS
  • TABLE 9 PATIENTS ON U.S. WAITING LISTS AT THE END OF THE YEAR BY TYPE OF ORGAN TRANSPLANT, 2003 - 2006
• TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS
  • TABLE 10 TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS, THROUGH 2013
• TRENDS IN TRANSPLANTATION OF ALL ORGANS
  • TABLE 11 U.S. ORGAN TRANSPLANTS, THROUGH 2006 (NUMBER OF PROCEDURES)
• INTERNATIONAL TRENDS
  • TABLE 12 NUMBERS OF DONATED CADAVERS BY REGION, 2003 - 2006
• LIMITED SUPPLY CURTAILS TRANSPLANTATIONS
• Living Donor Programs
• KEY FACTORS IN INDUSTRY GROWTH
• Reducing Demand
• Patient Survival Rates
  • TABLE 13 ONE-YEAR AND FIVE-YEAR PATIENT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997 - 2004 (%)
  • TABLE 14 ONE-YEAR AND FIVE-YEAR GRAFT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997 - 2004 (%)
  • TABLE 14 (CONTINUED)
  • TABLE 15 NUMBER OF PEOPLE IN THE U.S. LIVING WITH A FUNCTIONING TRANSPLANT BY TYPE, 2000 - 2005*
• Organ Substitutes
• Organs from Animals: Xenotransplantation
• Organ Primordia
• Nuclear Transfer to Eliminate the Rejection Gene
• Porcine Endogenous Retrovirus
• ARTIFICIAL ORGANS
• CELLULAR TRANSPLANTS
• KEY FACTORS INHIBITING GROWTH
• LACK OF DONORS
• ALTERNATIVE THERAPIES
• CULTURAL STIGMAS

• GOVERNMENT REGULATIONS
• THE MEDICARE DRUG DISCOUNT CARD PROGRAM, MEDICARE DRUG BENEFITS, AND TRANSPLANT PATIENTS
  • TABLE 16 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*
  • TABLE 17 MEDICARE IMMUNOSUPPRESIVE DRUG COVERAGE OVERVIEW

• HLA TISSUE TYPING
• THE WORLD MARKET FOR HLA TYPING
  • TABLE 18 WORLD MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
• THE U.S. MARKET FOR HLA TYPING
  • TABLE 19 U.S. MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
• ORGAN PRESERVATION PRODUCTS
  • TABLE 20 PRESERVATION TIME FOR TRANSPLANTED ORGANS (HOURS)
• Custodiol
• Warm Organ Perfusion
• IMMUNOSUPPRESSION
  • TABLE 21 IMMUNOSUPPRESSIVE DRUGS APPROVED IN THE U.S. BY CLASS
• Antibodies
  • TABLE 22 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION
  • TABLE 23 COMMONLY USED INTRAVENOUS ANTIBODY IMMUNOSUPPRESIVE DRUGS
  • TABLE 23 (CONTINUED)
• OKT-3
• Zenapax
• Simulect
• Campath/MabCampath
• Polyclonal Antibody Products
• Atgam
• Thymoglobulin
• The Market for Antibody Products to Treat Organ Transplant Rejection
  • TABLE 24 GLOBAL MARKET FOR ANTIBODY PRODUCTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2013 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET FOR ANTIBODY PRODUCTS USED IN ORGAN TRANSPLANTATION, 2007-2013 ($ MILLIONS)
• Antiproliferative Agents
• Azathioprine
• CellCept
• Myfortic
  • TABLE 25 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 3 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS, 2007-2013 ($ MILLIONS)
• Calcineurin Inhibitors
• Tacrolimus
• Cyclosporine
• Generic Cyclosporine
  • TABLE 26 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR CALCINEURIN INHIBITORS, 2007-2013 ($ MILLIONS)
• Source: BCC Research
• M-TOR Inhibitors
• Certican
• Rapamune
  • TABLE 27 GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
• Concern About Generics
  • TABLE 28 U.S. SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 5 U.S. SALES OF IMMUNOSUPPRESSIVES, BY CATEGORY, THROUGH 2013 ($ MILLIONS)
• IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT
  • TABLE 29 SELECTED IMMUNOSUPPRESSIVE AGENTS IN PHASE 1 OR LATER DEVELOPMENT
  • TABLE 29 (CONTINUED)
• TOLERANCE
• Antisense Therapy
• Costimulation
• Chimerism
• USUAL ANTI-REJECTION DRUG PROTOCOLS
  • TABLE 30 COMMON IMMUNOSUPPRESSIVE REGIMENS
• INDUCTION THERAPY
  • TABLE 31 IMMUNOSUPPRESSANT USE FOR INDUCTION, BY ORGAN IN 2006 (%)
• MAINTENANCE THERAPY
  • TABLE 32 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT DISCHARGE BY ORGAN IN THE U.S., 2006 (%)
  • TABLE 33 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT 1-YEAR POST-TRANSPLANT BY ORGAN IN U.S., 2006 (%)
• REJECTION THERAPY
• Risks Associated with Immunosuppressive Therapy
• Annual Cost of Immunosuppressant Drugs
• The World Market for Immunosuppressant Drug Therapy
  • TABLE 34 WORLDWIDE MARKET FOR IMMUNOSUPPRESSION IN SOLID ORGAN TRANSPLANT RECIPIENTS, THROUGH 2013
  • TABLE 35 GLOBAL SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 6 WORLDWIDE SALES OF IMMUNOSUPPRESSANTS BY CATEGORY, 2007-2013 ($ MILLIONS)
  • TABLE 36 WORLDWIDE SALES OF BRAND NAME IMMUNOSUPPRESSANT DRUGS BY COMPANY, 2006 AND 2007 ($ MILLIONS)
• PRODUCTS
• ADDRESSING INFECTION
• GRAFT-VERSUS-HOST DISEASE
• POST-TRANSPLANT INFECTIONS
• ViroPharma Incorporated
• Cardiovascular Disease
  • TABLE 37 COMMON POST-TRANSPLANT INFECTIONS
  • TABLE 38 TIMELINE FOR POST-TRANSPLANT INFECTION
  • TABLE 39 COMMON POST-TRANSPLANT DRUGS
  • TABLE 40 WORLD MARKET FOR ANTI-INFECTIVES USED FOR TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• POST-TRANSPLANT MONITORING
  • TABLE 41 U.S. MARKET FOR POST-TRANSPLANT MONITORING, THROUGH 2013 ($ MILLIONS)
• Cylex

• INCREASING SUPPLY
• SUPPLY MANAGEMENT
• REDUCING WASTE AND REJECTION
• INCREASING THE HARVEST
  • TABLE 42 RECOVERED ORGANS NOT USED BY TYPE, 2003 - 2006
  • TABLE 43 CONSENTED ORGANS NOT RECOVERED BY TYPE, 2003 - 2006
• BETTER HARVESTING
• DEFINITION OF BRAIN DEATH
• PROTECTING HARVESTED ORGANS
• HORMONAL RESUSCITATION
• NON-HEART-BEATING DONORS
• LESS WASTE
• PRESERVATION
• ORGAN PRESERVATION METHODS
• Rinse and Preservation Solutions
  • TABLE 44 MAJOR ORGAN PRESERVATION SOLUTIONS
• Celsior
• Collins Solution
• Custodiol
• Hypothermosol
• ViaSpan
• Market for Preservation Solutions
  • TABLE 45 NORTH AMERICAN AND WORLD MARKETS FOR ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORK COCKTAIL), THROUGH 2013 ($ MILLIONS)
• Organ Preservation Products in Development
• Human BioSystems
• Trophic Solutions
• Machine Perfusion
• Waters Medical Systems
• TransMedics, Inc.
• FIGHTING REJECTION
  • TABLE 46 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2003 - 2006

• TRANSPLANT CENTERS
  • TABLE 47 LEADING U.S. TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
• TESTING
• Blood Typing
• Tissue Typing
• Panel Reactive Antibodies (PRA)
  • TABLE 48 TISSUE TYPING TECHNOLOGIES
• Advances
  • TABLE 49 SELECTED COMPETITORS IN THE HLA TYPING MARKET
• Plasmapheresis: Transplantation without Matching Antigens
• KIDNEY
• MARKET FOR KIDNEY TRANSPLANTS
  • TABLE 50 U.S. MARKET FOR KIDNEY-ONLY TRANSPLANTATION, THROUGH 2013
• MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANTATION
  • TABLE 51 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLION)
• IMMUNOSUPPRESSION
• Drugs Used for Induction
  • TABLE 52 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN KIDNEY TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 53 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER KIDNEY TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and One-year Post-transplant
  • TABLE 54 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POST-TRANSPLANT FOR KIDNEY TRANSPLANTATION, 2002 - 2005 (%)
• ALTERNATIVES
• Mechanical
• Medical
• Animal
• Cellular
• PANCREAS
• MARKET FOR PANCREAS TRANSPLANTATION
  • TABLE 55 U.S. MARKET FOR PANCREAS TRANSPLANTATION, THROUGH 2013
• WAITING LIST
  • TABLE 56 U.S. PANCREAS WAITING LIST, THROUGH 2013
• IMMUNOSUPPRESSION
  • TABLE 57 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR PANCREAS TRANSPLANT PATIENTS, THROUGH 2013
• Drugs Used for Induction
  • TABLE 58 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN PANCREAS TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 59 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER PANCREAS TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and One-year Post-transplant
  • TABLE 60 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT FOR PANCREAS TRANSPLANTATION, 2002 - 2005 (%)
• PREVALANCE OF DIABETES
• ALTERNATIVES
• HEART
  • TABLE 61 U.S. HEART TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
• SUPPLY
• Cultural Backlash
• Accepting Brain Death is Crucial
• WAITING LISTS
• IMMUNOSUPPRESSION
  • TABLE 62 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART TRANSPLANT PATIENTS, THROUGH 2013
• Drugs Used for Induction
  • TABLE 63 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 64 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART TRANSPLANTATION, 2003 - 2006 (%)
  • TABLE 64 (CONTINUED)
• Drugs Used for Anti-rejection between Discharge and 1-year Post-transplant
  • TABLE 65 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN HEART TRANSPLANTATION, 2002 - 2005
• INDICATIONS
  • TABLE 66 LEADING CAUSES OF HEART FAILURE, 2002 - 2006 (%)
• TISSUE TYPING
• PRESERVATION
• ALTERNATIVES
• LIVER
• HISTORY
• TRANSPLANT STATISTICS
• ORGAN RECOVERY
• THE MARKET FOR LIVER TRANSPLANTATION
  • TABLE 67 U.S. LIVER TRANSPLANT MARKET, FIRST YEAR, THROUGH 2013 ($ MILLIONS)
• DONORS
• WAITING LISTS
  • TABLE 68 REGIONAL GROWTH IN LIVER WAITING LISTS, THROUGH 2013
• IMMUNOSUPPRESSION
• Drugs Used for Induction
  • TABLE 69 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LIVER TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 70 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LIVER TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-transplant
  • TABLE 71 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT FOR LIVER TRANSPLANTATION, 2002 - 2005 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 72 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT FOR LIVER TRANSPLANTATION, 2002 - 2005 (%)
  • TABLE 72 (CONTINUED)
• The Market for Immunosuppressive Drugs in Liver Transplantation
  • TABLE 73 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LIVER TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• INDICATIONS
• Causes of Cirrhosis
• TISSUE TYPING
• ORGAN REJECTION
  • TABLE 74 LIVER TRANSPLANT SURVIVAL RATES IN THE U.S. AND EUROPE, 2003 (%)
• LUNGS
• TRANSPLANTATION STATISTICS
• THE MARKET FOR LUNG TRANSPLANTATION
  • TABLE 75 U.S. LUNG TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
• WAITING LISTS
• INDICATIONS
  • TABLE 76 LEADING CAUSES OF CHRONIC LUNG FAILURE IN THE U.S., 2002 - 2006 (%)
• DONATION
• IMMUNOSUPPRESSION
  • TABLE 77 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• Drugs Used for Induction
  • TABLE 78 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 79 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LUNG TRANSPLANTATION, 2002 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
  • TABLE 80 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 81 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN LUNG TRANSPLANTATION, 2002 - 2005 (%)
  • TABLE 81 (CONTINUED)
• REJECTION
  • TABLE 82 U.S. LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES* (%)
• ALTERNATIVES
• HEART-LUNG
• THE MARKET FOR HEART-LUNG TRANSPLANTATION
  • TABLE 83 U.S. HEART-LUNG TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
• IMMUNOSUPPRESSION
  • TABLE 84 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• Drugs Used for Induction
  • TABLE 85 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART-LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 86 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART-LUNG TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
  • TABLE 87 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002 - 2005 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 88 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002 - 2005 (%)
• WAITING LISTS
  • TABLE 89 U.S. HEART-LUNG WAITING LIST TRENDS, THROUGH 2013
• SURVIVAL RATES
  • TABLE 90 U.S. HEART-LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES (%)
• INTESTINE/SMALL BOWEL
• HISTORY
• TRANSPLANT TYPES
• INDICATIONS
  • TABLE 91 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: ADULT PATIENTS
  • TABLE 92 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: PEDIATRIC PATIENTS
• U.S. TRANSPLANTATION STATISTICS
  • TABLE 93 U.S. SMALL BOWEL TRANSPLANTATION TRENDS, THROUGH 2013
• THE MARKET FOR INTESTINE TRANSPLANTATION
  • TABLE 94 U.S. SMALL BOWEL TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
• COUNTRIES WITH SMALL BOWEL/INTESTINES TRANSPLANT PROGRAMS
  • TABLE 95 COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS
• IMMUNOSUPPRESSION
  • TABLE 96 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
• Drugs Used for Induction
  • TABLE 97 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN INTESTINE TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance Prior to Discharge
  • TABLE 98 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN INTESTINE TRANSPLANTATION, 2003 - 2006 (%)
• Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
  • TABLE 99 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POST-TRANSPLANT IN INTESTINE TRANSPLANTATION, 2002 - 2005 (%)
• Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
  • TABLE 100 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTI-REJECTION BETWEEN TRANSPLANT AND 1-YEAR POST-TRANSPLANT IN INTESTINE TRANSPLANTATION, 2002 - 2005 (%)
  • TABLE 100 (CONTINUED)
• INFECTION PROPHYLAXIS
• ALTERNATIVES

• OVERVIEW
• FEWER DONATIONS DUE TO PUBLIC MISTRUST
• Compensation
• Cosmetic Tissue Usage
• CORNEA
• HISTORY
• GLOBAL ESTIMATES OF VISUAL IMPAIRMENT
• CORNEAL TRANSPLANTS IN THE U.S.
  • TABLE 101 U.S. CORNEAL TRANSPLANT MARKET, THROUGH 2013
• Waiting Lists
• Waiting Lists: Other Countries
• Tissue Testing
• Preservation
• Cryopreservation
• Immunosuppression
• ALTERNATIVES
• BLOOD STEM CELLS
• HISTORY
• First Successful Transplant
• Donor Registry Established
• INDICATIONS
• Cord Blood
• Cord Blood Banking
• PROCEDURE VOLUMES
  • TABLE 102 PROJECTED U.S. HEMATOPOIETIC STEM CELL TRANSPLANT PROCEDURES, THROUGH 2013
• Autologous Versus Allogeneic
• DONORS
  • TABLE 103 BMDW MEMBER HOME COUNTRIES
• Blood Collection in the U.S.
  • TABLE 104 NUMBER OF BONE MARROW DONORS, BY COUNTRY
• WAITING LISTS
• REJECTION
• IMMUNOSUPPRESSION
• Enzo Biochem
• MARKET FOR IMMUNOSUPPRESSANTS IN BLOOD STEM CELL TRANSPLANTS
  • TABLE 105 U.S. MARKET FOR IMMUNOSUPPRESSIVE DRUG THERAPY FOLLOWING HEMATOPOIETIC TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
• CORD BLOOD
• Increasing the Number of Cord Blood Cells
• BONE GRAFT TRANSPLANTATION
• HISTORY
• GLOBAL BONE GRAFT MARKET
• PROCEDURES
  • TABLE 106 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2013
  • FIGURE 7 U.S. BONE GRAFT PROCEDURES, 2007-2013 ($ MILLIONS)
• Spinal Fusion
• Joint Replacement
• INDICATIONS
• ORTHOPEDIC IMPLANT MARKET
  • TABLE 107 U.S. AND WORLDWIDE ORTHOPEDIC IMPLANT MARKET GROWTH, THROUGH 2013 ($ MILLIONS)
  • TABLE 108 U.S. ORTHOPEDIC IMPLANT MARKET BY NUMBER AND TYPE OF PROCEDURE, THROUGH 2013
• AUTOGRAFTS
• Autografts (Continued)
  • TABLE 109 U.S. AND WORLD VALUES OF THE BONE GRAFTING MARKET, THROUGH 2013 ($ MILLIONS)
• ALLOGRAFTS
• Allografts (Continued)
• Risks Associated with Allografts
• Products
• Base Tissue
• Demineralized Bone Matrix Products
• Machined Implants
• THE ORTHOBIOLOGICS MARKET
  • TABLE 110 GLOBAL ORTHOBIOGICS MARKET, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
• The Market for Allografted Tissue
  • TABLE 111 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, THROUGH 2013 ($ MILLIONS)
  • FIGURE 8 BONE ALLOGRAFT MARKET, THROUGH 2013 ($ MILLIONS)
• BONE GRAFT SUBSTITUTES
  • TABLE 112 COMPARISON OF BONE GRAFT MATERIALS
  • TABLE 113 SUBSTITUTE BONE GRAFT
• FACTOR-BASED BONE GRAFT SUBSTITUTES
• Factor-Based Bone Graft ..... (Continued)
• Bone Morphogenic Proteins (BMPs)
• InductOs
• INFUSE Bone Graft
• OP-1 Implant
• PREVENTING INFECTION
• PRESERVATION
• COMPETITION
• VASCULAR TRANSPLANTATION
• HISTORY
• INDICATIONS
• PROCEDURES
• DONORS
• HEART VALVES
• HEART VALVE ALLOGRAFT MARKET
  • TABLE 114 U.S. HEART VALVE TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
• TISSUE TESTING
• SYNTHETICS
• XENOGRAFTS
• ADVANCES
• Symetis
• Edwards Life Sciences
• BETTER MONITORING
• TISSUE VALVES GAIN POPULARITY
• MAJOR COMPETITORS
• VASCULAR GRAFTS
• Indications
• Waiting List
• Products
• ALTERNATIVES TO VASCULAR TRANSPLANTATION
• SKIN TRANSPLANTATION
  • TABLE 115 U.S. MARKET FOR HUMAN SKIN-BASED PRODUCTS, THROUGH 2013
• HISTORY
• MARKET POTENTIAL
• INDICATIONS
• Burns
• Other Injuries
• Cosmetic Surgery
• Wounds
• Venous Ulcers
  • TABLE 116 ESTIMATED INCIDENCE OF VENOUS ULCERS IN THE U.S. OVER-64 POPULATION, THROUGH 2013
• Diabetic Ulcers
  • TABLE 117 ESTIMATED U.S. INCIDENCE OF DIABETIC FOOT ULCERS, THROUGH 2013 (MILLIONS)
• Pressure Ulcers
• Urinary Incontinence and Other Uses
• Collagen Meniscus Implant
• REJECTION
• TISSUE TESTING
• PRESERVATION
• CELLULAR TRANSPLANTATION
• HISTORY
• INDICATIONS
• TYPES OF CELLS
• DONORS
• REJECTION
• GOVERNMENT REGULATIONS
• ALTERNATIVES

• ALTERNATIVES TO CORNEAL TRANSPLANTATION
• SURGICAL
• ARTIFICIAL CORNEAS
• RETINAL TRANSPLANTS
• CELLULAR TRANSPLANTS
• ELECTRONIC IMPLANTS
• ALTERNATIVES TO INTESTINAL TRANSPLANTATION
• MEDICAL
• CELLULAR
• ALTERNATIVES TO PANCREAS TRANSPLANTATION
• MEDICAL
• Islet Cell Transplantation
• Islet Cell Transplantation (Continued)
• Drawbacks
• Cell Encapsulation
• ReNeuron
• Bioartificial Pancreas
• Cerco Medical
• Cultured Stem Cells
• Diminished Need for Transplantation in the Future
• COSTS
• ALTERNATIVES TO HEART TRANSPLANTATION
• MEDICAL
• Fibroblast Growth Factors
• CardioVascular BioTherapeutic, Inc.
• Endovasc, Ltd.
• Gene Therapy
• Naked Plasmid DNA Transfer
• Adenoviral Vectors
• XENOTRANSPLANTATION
• SURGICAL
• Laser Revascularization
• Mitral Valve Repair
• CARDIAC SUPPORT DEVICES
• Passive Support Systems
• MECHANICAL
• REGENERATION INSTEAD OF REPLACEMENT
• Biophan
• MECHANICAL ORGANS
• VAD Market
• VAD costs
  • TABLE 118 GLOBAL MARKET FOR VADS, THROUGH 2013 ($ MILLIONS)
  • TABLE 119 U.S. MARKET FOR VADS USED AS DESTINATION THERAPY, THROUGH 2013 ($ MILLIONS)
• DeBakey LVAS
• HeartMate
• Incor LVAD, Excor VAD
• Novacor
• VAD DEVELOPMENT IN THE U.S.
  • TABLE 120 LEFT VENTRICULAR ASSIST DEVICES IN DEVELOPMENT
• Arrow International
• CardiacAssist
• Jarvik
• Ventracor
• TOTAL ARTIFICIAL HEARTS
• AbioMed
• CardioWest
• OTHER CARDIAC ASSIST DEVICES IN DEVELOPMENT
• CELLULAR THERAPY
• Bioheart
• ALTERNATIVES TO LIVER TRANSPLANTATION
• MEDICAL
• Vertex Pharmaceuticals
• ARTIFICIAL LIVERS
• CHEMICAL/MECHANICAL AND/OR BIOARTIFICIAL LIVERS
  • TABLE 121 INDICATIONS FOR THE BIOARTIFICIAL LIVER
• Chemical/Mechanical.....(Continued)
  • TABLE 122 BIOARTIFICIAL LIVERS IN DEVELOPMENT
• Bioartificial Liver Support System
• ELAD
• Modular Extracorporeal Liver Support (MELS)
• Molecular Adsorption Recycling System (MARS)
• RELATIVE COSTS
• ALTERNATIVES TO LUNG TRANSPLANTATION
• MEDICAL
• SURGICAL
• ALTERNATIVES TO BONE GRAFTS
• MEDICAL
• SYNTHETIC MATERIALS
• Orthovita
• Spine Wave
• ReGen Biologics
• ALTERNATIVES TO VASCULAR TRANSPLANTATION
• ANIMAL
• Stentless Valves
• Calcification
• SURGICAL
• Angioplasty and Stents
• MEDICAL
• MECHANICAL/SYNTHETIC
• ALTERNATIVES TO VASCULAR TRANSPLANTATION
• TISSUE ENGINEERING OF VASCULAR GRAFTS
• GENE THERAPY
• ALTERNATIVES TO SKIN TRANSPLANTATION
• ANIMAL-BASED PRODUCTS
• Biobrane
• OaSIS
• GROWTH FACTORS
• ARTIFICIAL SKIN/SKIN REPLACEMENT PRODUCTS
• AlloDerm
• Apligraf
• Cymetra
• Dermagraft
• Epicel
• Integra Products
• OrCel
• TransCyte
• MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS
  • TABLE 123 MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACMENT PRODUCTS
• THE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS
  • TABLE 124 ESTIMATED WORLDWIDE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($ MILLIONS)
  • TABLE 125 ESTIMATED U.S. MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($ MILLIONS)
• PRODUCTS IN DEVELOPMENT
• Altex Plus, Ltd.
• Cytomedix
• Geron
• OTHER RESEARCH
• REGULATION

• ABIOMED, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ARBIOS SYSTEMS, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ARROW INTERNATIONAL
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ASTELLAS PHARMA, INC
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• CRYOLIFE, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• DEPUY ORTHOPEDICS
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• EDWARDS LIFESCIENCES
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• EXACTECH
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• FORTICELL BIOSCIENCE
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• FRESENIUS MEDICAL CARE AG & CO. KGAA
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• GENZYME
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• HEMOCLEANSE, INC
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• JOHNSON & JOHNSON
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• KIADIS PHARMA
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• KINETIC CONCEPTS, INC. (KCI)
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• LIFEBLOOD MEDICAL, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• LIFECELL CORP. (SEE KINETIC CONCEPTS, INC)
• LIFECYCLE PHARMA A/S
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• LIVING CELL TECHNOLOGIES, LTD.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• MEDTRONIC, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• NOVARTIS AG
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ON-X LIFE TECHNOLGIES, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• ORGANOGENESIS, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• OSTEOTECH
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• PDL BIOPHARMA
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• ROCHE PHARMACEUTICALS
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• SORIN GROUP, S.P.A.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• ST. JUDE MEDICAL
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• STRYKER CORPORATION
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• SYNCARDIA SYSTEMS, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• SYTHES (US)
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• TRANSMEDICS, INC.
• BUSINESS OVERVIEW
• FINANCIALS
• PRODUCTS
• THORATEC CORP.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• VENTRACOR
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• VIROPHARMA, INC.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• WORLD HEART CORP.
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS
• WYETH
• BUSINESS OVERVIEW
• FINANCIAL INFORMATION
• PRODUCTS